{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T08:05:25Z","timestamp":1774771525018,"version":"3.50.1"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Kidney stones are frequent in industrialized countries with a lifetime risk of 10 to 15%. A high percentage of individuals experience recurrence. Calcium-containing stones account for more than 80% of kidney stones. Diet, environmental factors, behavior, and genetic variants contribute to the development of kidney stones. Osteocytes excrete the 21\u00a0kDa glycoprotein sclerostin, which inhibits bone formation by osteoblasts. Animal data suggests that sclerostin might directly or indirectly regulate calcium excretion via the kidney. As hypercalciuria is one of the most relevant risk factors for kidney stones, sclerostin might possess pathogenic relevance in nephrolithiasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a prospective cross-sectional observational controlled study in 150 recurrent kidney stone formers (rKSF) to analyse the association of sclerostin with known stone risk factors and important modulators of calcium-phosphate metabolism. Serum sclerostin levels were determined at the first visit. As controls, we used 388 non-stone formers from a large Swiss epidemiological cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sclerostin was mildly increased in rKSF in comparison to controls. This finding was more pronounced in women compared to men. Logistic regression indicated an association of serum sclerostin with rKSF status. In hypercalciuric individuals, sclerostin levels were not different from normocalciuric patients. In Spearman correlation analysis we found a positive correlation between sclerostin, age, and BMI and a negative correlation with eGFR. There was a weak correlation with iPTH and intact FGF 23. In contrast, serum sclerostin levels were not associated with 25-OH Vitamin D3, 1,25-dihydroxy-Vitamin D3, urinary calcium and phosphate or other urinary lithogenic risk factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This is the first prospective controlled study investigating serum sclerostin in rKSF. Sclerostin levels were increased in rKSF independent of hypercalciuria and significantly associated with the status as rKSF. It appears that mechanisms other than hypercalciuria may be involved and thus further studies are required to elucidate underlying pathways.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfad256","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T17:15:00Z","timestamp":1699290900000},"source":"Crossref","is-referenced-by-count":2,"title":["Serum sclerostin is associated with recurrent kidney stone formation independent of hypercalciuria"],"prefix":"10.1093","volume":"17","author":[{"given":"Daniel","family":"Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Gurevich","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soroush","family":"Mohammadi Jouabadi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Division of Vascular Medicine and Pharmacology, Erasmus Medical Center, University Medical Center Rotterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Maria","family":"Pastor Arroyo","sequence":"additional","affiliation":[{"name":"Institute of Physiology, University of Zurich , Zurich , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Ritter","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Estoppey Younes","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine (IUMSP), University of Lausanne , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten A","family":"Wagner","sequence":"additional","affiliation":[{"name":"Institute of Physiology, University of Zurich , Zurich , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Henrique","family":"Imenez Silva","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center, University Medical Center Rotterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1552-7983","authenticated-orcid":false,"given":"Harald","family":"Seeger","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich , Switzerland"},{"name":"Institute of Physiology, University of Zurich , Zurich , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilufar","family":"Mohebbi","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich , Switzerland"},{"name":"Institute of Physiology, University of Zurich , Zurich , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"key":"2024010515584213000_bib1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eururo.2012.03.052","article-title":"Prevalence of kidney stones in the United States","volume":"62","author":"Scales","year":"2012","journal-title":"Eur Urol"},{"key":"2024010515584213000_bib2","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.7326\/0003-4819-111-12-1006","article-title":"The first kidney stone","volume":"111","author":"Uribarri","year":"1989","journal-title":"Ann Intern Med"},{"key":"2024010515584213000_bib3","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.2013.8780","article-title":"History of kidney stones and the risk of coronary heart disease","volume":"310","author":"Ferraro","year":"2013","journal-title":"JAMA"},{"key":"2024010515584213000_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00240-016-0938-x","article-title":"Nephrolithiasis as a risk factor of chronic kidney disease: a meta-analysis of cohort studies with 4,770,691 participants","volume":"45","author":"Zhe","year":"2017","journal-title":"Urolithiasis"},{"key":"2024010515584213000_bib5","first-page":"16","article-title":"Etiopathogenic factors of urolithiasis","volume":"74","author":"Wagner","year":"2021","journal-title":"Arch Esp Urol"},{"key":"2024010515584213000_bib6","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1172\/JCI26662","article-title":"Kidney stone disease","volume":"115","author":"Coe","year":"2005","journal-title":"J Clin Invest"},{"key":"2024010515584213000_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(06)68071-9","article-title":"Kidney stones: pathophysiology and medical management","volume":"367","author":"Moe","year":"2006","journal-title":"Lancet"},{"key":"2024010515584213000_bib8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.ki.5002441","article-title":"Genetics of hypercalciuric stone forming diseases","volume":"72","author":"Devuyst","year":"2007","journal-title":"Kidney Int"},{"key":"2024010515584213000_bib9","first-page":"S165","article-title":"Urinary pH and stone formation","volume":"23 Suppl 16","author":"Wagner","year":"2010","journal-title":"J Nephrol"},{"key":"2024010515584213000_bib10","doi-asserted-by":"crossref","first-page":"c159","DOI":"10.1159\/000317196","article-title":"An update and practical guide to renal stone management","volume":"116","author":"Johri","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"2024010515584213000_bib11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1210\/jc.2005-1606","article-title":"Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak","volume":"91","author":"Rendina","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2024010515584213000_bib12","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1159\/000080256","article-title":"Hypophosphatemia and calcium nephrolithiasis","volume":"98","author":"Prie","year":"2004","journal-title":"Nephron Exp Nephrol"},{"key":"2024010515584213000_bib13","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1523-1755.2001.00796.x","article-title":"Frequency of renal phosphate leak among patients with calcium nephrolithiasis","volume":"60","author":"Prie","year":"2001","journal-title":"Kidney Int"},{"key":"2024010515584213000_bib14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum Mol Genet"},{"key":"2024010515584213000_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot\u2013Containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2024010515584213000_bib16","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a wnt signaling inhibitor","volume":"280","author":"Sem\u00ebnov","year":"2005","journal-title":"J Biol Chem"},{"key":"2024010515584213000_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"key":"2024010515584213000_bib18","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1073\/pnas.1221255110","article-title":"Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium","volume":"110","author":"Ryan","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024010515584213000_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00223-010-9372-1","article-title":"Sclerostin: current knowledge and future perspectives","volume":"87","author":"Moester","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"2024010515584213000_bib20","doi-asserted-by":"crossref","first-page":"i119","DOI":"10.1136\/ard.2010.141150","article-title":"Targeting sclerostin as potential treatment of osteoporosis","volume":"70 Suppl 1","author":"Papapoulos","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024010515584213000_bib21","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00016.2003","article-title":"FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization","volume":"285","author":"Quarles","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2024010515584213000_bib22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024010515584213000_bib23","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1210\/jc.2004-2238","article-title":"A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis","volume":"90","author":"Larsson","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2024010515584213000_bib24","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"key":"2024010515584213000_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","article-title":"Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23","volume":"61","author":"Bergwitz","year":"2010","journal-title":"Annu Rev Med"},{"key":"2024010515584213000_bib26","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/ki.2011.27","article-title":"Phosphate and FGF-23","volume":"79","author":"Juppner","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"2024010515584213000_bib27","doi-asserted-by":"crossref","first-page":"F785","DOI":"10.1152\/ajprenal.00250.2021","article-title":"Fibroblast growth factor 23 leads to endolysosomal routing of the renal phosphate cotransporters NaPi-IIa and NaPi-IIc in vivo","volume":"321","author":"K\u00fcng","year":"2021","journal-title":"Am J Physiol Renal Physiol"},{"key":"2024010515584213000_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-physiol-021119-034650","article-title":"Regulation and effects of FGF23 in chronic kidney disease","volume":"82","author":"Musgrove","year":"2020","journal-title":"Annu Rev Physiol"},{"key":"2024010515584213000_bib29","doi-asserted-by":"crossref","first-page":"E840","DOI":"10.1210\/jc.2011-1528","article-title":"A functional allelic variant of the FGF23 gene is associated with renal phosphate leak in calcium nephrolithiasis","volume":"97","author":"Rendina","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2024010515584213000_bib30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2215\/CJN.07060714","article-title":"Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones","volume":"10","author":"Taylor","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024010515584213000_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ndt\/gfy170","article-title":"Distinct phenotype of kidney stone formers with renal phosphate leak","volume":"34","author":"Dhayat","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2024010515584213000_bib32","doi-asserted-by":"crossref","first-page":"e92522","DOI":"10.1371\/journal.pone.0092522","article-title":"Epidemiology of masked and white-coat hypertension: the family-based SKIPOGH study","volume":"9","author":"Alwan","year":"2014","journal-title":"PLoS One"},{"key":"2024010515584213000_bib33","doi-asserted-by":"crossref","first-page":"E1159","DOI":"10.1210\/jc.2011-0254","article-title":"Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays","volume":"96","author":"McNulty","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2024010515584213000_bib34","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2215\/CJN.05660614","article-title":"Stone composition as a function of age and sex","volume":"9","author":"Lieske","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024010515584213000_bib35","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.eururo.2014.10.029","article-title":"Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines","volume":"67","author":"Skolarikos","year":"2015","journal-title":"Eur Urol"},{"key":"2024010515584213000_bib36","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fphys.2019.00304","article-title":"The EPO-FGF23 signaling pathway in erythroid progenitor cells: opening a new area of research","volume":"10","author":"van Vuren","year":"2019","journal-title":"Front Physiol"},{"key":"2024010515584213000_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"2024010515584213000_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"2024010515584213000_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5527\/wjn.v3.i4.282","article-title":"Usefulness of hounsfield unit and density in the assessment and treatment of urinary stones","volume":"3","author":"G\u00fcc\u00fck","year":"2014","journal-title":"World J Nephrol"},{"key":"2024010515584213000_bib40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.urology.2013.01.015","article-title":"Using Hounsfield unit measurement and urine parameters to predict uric acid stones","volume":"82","author":"Spettel","year":"2013","journal-title":"Urology"},{"key":"2024010515584213000_bib41","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.3390\/jcm12155027","article-title":"Urinary calcium is associated with serum sclerostin among stone formers","volume":"12","author":"Rodrigues","year":"2023","journal-title":"J Clin Med"},{"key":"2024010515584213000_bib42","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/ndt\/gfu350","article-title":"Effect of being overweight on urinary metabolic risk factors for kidney stone formation","volume":"30","author":"Shavit","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2024010515584213000_bib43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00198-012-1978-x","article-title":"Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study","volume":"24","author":"Garnero","year":"2013","journal-title":"Osteoporos Int"},{"key":"2024010515584213000_bib44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2011-2152","article-title":"Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults","volume":"97","author":"Amrein","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2024010515584213000_bib45","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1210\/jc.2012-1901","article-title":"Sclerostin levels associated with inhibition of the wnt\/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus","volume":"97","author":"Gaudio","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2024010515584213000_bib46","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1210\/jc.2013-1521","article-title":"Sclerostin: another vascular calcification inhibitor?","volume":"98","author":"Claes","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2024010515584213000_bib47","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/ki.2015.258","article-title":"Sclerostin levels in CKD patients: an important, but not definitive, step on the way to clinical use","volume":"88","author":"Delanaye","year":"2015","journal-title":"Kidney Int"},{"key":"2024010515584213000_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ndt\/gfv111","article-title":"Vascular calcification in chronic kidney disease: an update","volume":"31","author":"Schlieper","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2024010515584213000_bib49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2015.156","article-title":"Sclerostin and DKK1: new players in renal bone and vascular disease","volume":"88","author":"Evenepoel","year":"2015","journal-title":"Kidney Int"},{"key":"2024010515584213000_bib50","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/ki.2015.194","article-title":"Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification","volume":"88","author":"Qureshi","year":"2015","journal-title":"Kidney Int"},{"key":"2024010515584213000_bib51","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1093\/ndt\/gft039","article-title":"Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?","volume":"28","author":"Viaene","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2024010515584213000_bib52","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/ndt\/gfu301","article-title":"High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study","volume":"30","author":"Drechsler","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2024010515584213000_bib53","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2369-15-190","article-title":"Serum sclerostin is an independent predictor of mortality in hemodialysis patients","volume":"15","author":"Goncalves","year":"2014","journal-title":"BMC Nephrol"},{"key":"2024010515584213000_bib54","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s11255-016-1387-8","article-title":"Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis","volume":"48","author":"Kanbay","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"2024010515584213000_bib55","first-page":"1217","article-title":"Serum sclerostin: relation with mortality and impact of hemodiafiltration","volume":"32","author":"Lips","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2024010515584213000_bib56","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2215\/CJN.10030913","article-title":"Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers","volume":"9","author":"Menon","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024010515584213000_bib57","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s11255-019-02215-0","article-title":"Calcitriol and FGF-23, but neither PTH nor sclerostin, are associated with calciuria in CKD","volume":"51","author":"Ramalho","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"2024010515584213000_bib58","doi-asserted-by":"crossref","first-page":"5305014","DOI":"10.1155\/2019\/5305014","article-title":"The protective roles of estrogen receptor \u03b2 in renal calcium oxalate crystal formation via reducing the liver oxalate biosynthesis and renal oxidative stress-mediated cell injury","volume":"2019","author":"Zhu","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"2024010515584213000_bib59","doi-asserted-by":"crossref","first-page":"e0137350","DOI":"10.1371\/journal.pone.0137350","article-title":"Altered calcium and vitamin D homeostasis in first-time calcium kidney stone-formers","volume":"10","author":"Ketha","year":"2015","journal-title":"PLoS One"},{"key":"2024010515584213000_bib60","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/ndt\/gfx282","article-title":"Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know","volume":"33","author":"Delanaye","year":"2018","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad256\/52800093\/sfad256.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/1\/sfad256\/55105901\/sfad256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/1\/sfad256\/55105901\/sfad256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T15:59:52Z","timestamp":1704470392000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfad256\/7335735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,1]]},"published-print":{"date-parts":[[2024,1,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad256","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,11,1]]},"article-number":"sfad256"}}